Top

Published in:

01-05-2007 | Short Communication

Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases

Authors: K. Henriksen, L. B. Tanko, P. Qvist, P. D. Delmas, C. Christiansen, M. A. Karsdal

Published in: Osteoporosis International | Issue 5/2007

Abstract

Numerous experimental and clinical observations suggest that overall changes in bone resorption during menopause or treatment with hormone replacement therapy (HRT) are combined effects of changes in osteoclast number and function. Moreover, due to a coupling between osteoclastic bone resorption and osteoblastic bone formation, pronounced alteration of osteoclast number will eventually lead to alteration of osteoblastic bone formation. Fragments of type I collagen, such as the C- and N-terminal telopeptides of collagen type I (CTX and NTX, respectively), are generated during bone resorption and hence can be used as surrogate markers of osteoclast function. Circulating levels of different enzymes in the serum, such as TRAP 5b and cathepsin K are proportional to the number of osteoclasts, and hence can be used as surrogate markers of osteoclast number. Since antiresorptive effects can be obtained in different ways, we felt it was timely to discuss the different scenarios, highlight differences specific to different pharmacological interventions with different mechanisms of action, and discuss how these bone markers can assist us in a deeper analysis of the pharmacodynamics and safety profile of existing and upcoming drug candidates.

Baron R (2003) Anatomy and biology of bone matrix and cellular elements. Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 1–8

Martin TJ (1993) Hormones in the coupling of bone resorption and formation. Osteoporos Int 3(Suppl 1):121–125PubMedCrossRef

Vaananen HK, Harkonen PL (1996) Estrogen and bone metabolism. Maturitas 23 Suppl:S65–S69PubMed

Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 21:115–137PubMedCrossRef

Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289:1508–1514PubMedCrossRef

Garnero P, Sornay-Rendu E, Claustrat B et al (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526–1536PubMedCrossRef

Ravn P, Hosking D, Thompson D et al (1999) Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab 84:2363–2368PubMedCrossRef

Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237–244PubMedCrossRef

Holzer G, Noske H, Lang T (2005) Soluble cathepsin K: a novel marker for the prediction of nontraumatic fractures? J Lab Clin Med 146:13–17PubMedCrossRef

10.

Gertz BJ, Clemens JD, Holland SD et al (1998) Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment. Calcif Tissue Int 63:102–106PubMedCrossRef

11.

Woitge HW, Pecherstorfer M, Li Y (1999) Novel serum markers of bone resorption: clinical assessment and comparison with established urinary indices. J Bone Miner Res 14:792–801PubMedCrossRef

12.

Christgau S, Bitsch-Jensen O, Hanover BN et al (2000) Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy. Bone 26:505–511PubMedCrossRef

13.

Halleen JM, Alatalo SL, Suominen H et al (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337–1345PubMedCrossRef

14.

Kirstein B, Chambers TJ, Fuller K (2006) Secretion of tartrate-resistant acid phosphatase by osteoclasts correlates with resorptive behavior. J Cell Biochem 98:1085–1094PubMedCrossRef

15.

Schaller S, Henriksen K, Sveigaard C et al (2004) The chloride channel inhibitor n53736 prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:1144–1153PubMedCrossRef

16.

Karsdal MA, Henriksen K, Sorensen MG et al (2005) Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467–476PubMed

17.

Koh AJ, Demiralp B, Neiva KG et al (2005) Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology 146:4584–4596PubMedCrossRef

18.

Martin TJ, Sims NA (2005) Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:76–81PubMedCrossRef

19.

Reszka AA, Rodan GA (2003) Mechanism of action of bisphosphonates. Curr Osteoporos Rep 1:45–52PubMed

20.

Nenonen A, Cheng S, Ivaska KK et al (2005) Serum TRACP 5b Is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804–1812CrossRef

21.

McClung MR, Lewiecki EM, Cohen SB et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831PubMedCrossRef

22.

Hamdy NA (2006) Osteoprotegerin as a potential therapy for osteoporosis. Curr Rheumatol Rep 8:50–54PubMed

23.

Hannon RA, Clowes JA, Eagleton AC et al (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34:187–194PubMedCrossRef

24.

Tahtela R, Seppanen J, Laitinen K et al (2005) Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporos Int 16:1109–1116PubMedCrossRef

25.

Hansdottir H, Franzson L, Prestwood K et al (2004) The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities. J Am Geriatr Soc 52:779–783PubMedCrossRef

26.

Hannon RA, Clack G, Gallager N et al (2005) The effect of AZ0530, a highly selective SRC inhibitor, on bone turnover in healthy males. European Calcified Tissue Society Conference 2005 [Abstract nb OC042]

27.

Capparelli C, Morony S, Warmington KS et al (2000) Pharmacologic Effects of a Single Treatment with Osteoprotegerin (OPG) on Bone Remodeling and Bone Density in Normal Rats. J Bone Miner Res 15 [Suppl 1], abstract 1132

28.

Kostenuik P, Warmington KS, Grisanti M et al (2005) RANKL Inhibition with AMG 162, a Fully Human MAb, Causes Sustained Suppression of Bone Resorption and Increased BMD in Knockin Mice Expressing Humanized RANKL. J Bone Miner Res 20[Suppl 1], abstract SU304

29.

Karsdal MA, Hjorth P, Henriksen K et al (2003) Transforming growth factor-beta controls human osteoclastogenesis through the p38 MAPK and regulation of RANK expression. J Biol Chem 278:44975–44987PubMedCrossRef

30.

Henriksen K, Gram J, Schaller S et al (2004) Characterization of osteoclasts from patients harboring a G215R mutation in ClC-7 causing Autosomal Dominant Osteopetrosis type II (ADOII). Am J Pathol 164:1537–1545PubMed

31.

Bollerslev J, Marks SC Jr, Pockwinse S et al (1993) Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis. Bone 14:865–869PubMedCrossRef

32.

Alatalo SL, Ivaska KK, Waguespack SG et al (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883–890PubMedCrossRef

33.

Del Fattore A, Peruzzi B, Rucci N et al (2005) Clinical, genetic and cellular analysis of forty-nine osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43:315–325PubMedCrossRef

34.

Schlemmer A, Hassager C, Jensen SB et al (1992) Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women. J Clin Endocrinol Metab 74:476–480PubMedCrossRef

35.

Qvist P, Christgau S, Pedersen BJ et al (2002) Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31:57–61PubMedCrossRef

36.

Hart SM, Eastell R (1999) Biochemical markers of bone turnover. Curr Opin Nephrol Hypertens 8:421–427PubMedCrossRef

37.

Simmons DJ, Menton DN, Russell JE et al (1988) Bone cell populations and histomorphometric correlates to function. Anat Rec 222:228–236PubMedCrossRef

38.

Halleen JM (2003) Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res 23:1027–1029PubMed

39.

Ple PA, Green TP, Hennequin LF et al (2004) Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem 47:871–887PubMedCrossRef

40.

Meier C, Meinhardt U, Greenfield JR et al (2006) Serum cathepsin K concentrations reflect osteoclastic activity in women with postmenopausal osteoporosis and patients with Paget’s disease. Clin Lab 52:1–10PubMed

41.

Ljusberg J, Wang Y, Lang P et al (2005) Proteolytic excision of a repressive loop domain in tartrate-resistant acid phosphatase by cathepsin K in osteoclasts. J Biol Chem 280:28370–28381PubMedCrossRef

42.

Rissanen J, Suutari S, Ylonen S et al (2005) The Ratio of Osteoclast Activity/Osteoclast Number (CTX/TRACP 5b) Improves the Interpretation of the Effects of Anti-Resorptive Treatments in Human Osteclast Cultures. J Bone Miner Res 20[Suppl 1], abstract SU290

43.

Finkelstein JS, Hayes A, Hunzelman JL et al (2003) The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216–1226PubMedCrossRef

44.

Black DM, Greenspan SL, Ensrud KE et al (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215PubMedCrossRef

45.

Heaney RP (2003) Is the paradigm shifting? Bone 33:457–465PubMedCrossRef

Title: Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases
Authors: K. Henriksen
L. B. Tanko
P. Qvist
P. D. Delmas
C. Christiansen
M. A. Karsdal
Publication date: 01-05-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 5/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0286-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2007

Comparative study of axial and femoral bone mineral density and parameters of mandibular bone quality in patients receiving dental implants

Hospitalised osteoporotic vertebral fractures in Spain: Analysis of the national hospital discharge registry

Comment on Schott et al.: Which screening strategy using BMD measurements would be most cost effective for hip fracture prevention in elderly women? A decision analysis based on a Markov model

Prediction of absolute risk of non-spinal fractures using clinical risk factors and heel quantitative ultrasound

Unmet needs in fracture prevention: new European guidelines for the investigation and registration of therapeutic agents

Calcium-PTH-vitamin D axis in older patients with hip fracture